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Abstract
Aims: Data on procedural and clinical outcomes after transcatheter aortic valve implantation (TAVI) with 
the new-generation self-expanding Medtronic Evolut R prosthesis in comparison with its predecessor, the 
Medtronic CoreValve, are scarce. The aim of this study was to assess the safety and efficacy of the Evolut 
R device compared with the former-generation CoreValve.
Methods and results: In a nationwide, prospective, multicentre cohort study (Swiss TAVI registry, 
NCT01368250), outcomes of consecutive transfemoral TAVI patients treated with the new-generation 
Medtronic Evolut R (September 2014 - February 2016) and the Medtronic CoreValve (February 2011 - 
February 2016) were investigated. Events were reported according to VARC-2 and adjudicated by a clini-
cal events committee. During the study period, 317 and 678 consecutive patients underwent TAVI with 
the Evolut R and the CoreValve bioprosthesis, respectively. Baseline clinical characteristics between the 
groups were comparable, although Evolut R patients were lower risk according to the STS score (4.8±3.4% 
vs. 6.9±5.0%, p<0.001) and logistic EuroSCORE (17.3±13% vs. 20.1±13%, p=0.009). Implantation of the 
Evolut R was associated with a lower use of predilatation (48.1% vs. 72.4%, p<0.001), a shorter pro-
cedure time (67.9±36 min vs. 76.7±42 min, p=0.002), and less contrast dye use during the procedure 
(155.2±98 ml vs. 208.0±117 ml, p<0.001). Post-procedural mean gradient was comparable (7.4±4.7 mmHg 
vs. 7.5±5.0 mmHg), as were the 30-day rates of moderate to severe aortic regurgitation (8.5% vs. 10.5%), 
major vascular (9.8% vs. 10.3%) and life-threatening bleeding complications (5.4% vs. 5.3%), disabling 
stroke (1.9% vs. 1.6%), all-cause mortality (3.2% vs. 3.4%) as well as permanent pacemaker implantation 
(22.1% vs. 23.4%).
Conclusions: Thirty-day clinical outcomes were favourable and comparable between the Evolut R and the 
CoreValve bioprosthesis.
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Abbreviations
CE Conformité Européenne
Fr French
MACCE major adverse cardiac and cerebrovascular events
PCI percutaneous coronary intervention
PVL paravalvular leakage
STS Society of Thoracic Surgeons
TAVI transcatheter aortic valve implantation
THV transcatheter heart valve
VARC Valve Academic Research Consortium
Introduction
Transcatheter aortic valve implantation1 (TAVI) has developed 
from an experimental procedure into a routine intervention, espe-
cially suitable for elderly or high-risk patients. The recent avail-
ability of new-generation self-expanding transcatheter heart valves 
(THV) – with enhanced features, allowing recapture and reposi-
tioning of the prosthesis during valve deployment – may further 
improve outcomes after TAVI.
The latest CoreValve generation, the CoreValve® Evolut® R 
(referred to as Evolut R; Medtronic, Minneapolis, MN, USA), 
received CE mark approval in September 2014 for the 23 mm THV 
and in February 2015 for the 26 and 29 mm devices. As a conse-
quence, the Evolut R has replaced its predecessor in Switzerland 
with the exception of the 31 mm device (used in aortic annulus 
dimensions between 26 mm and 29 mm), which remains the pre-
vious-generation CoreValve® (Medtronic).
Currently, periprocedural and clinical outcome data for the 
Evolut R are limited to the CE mark trial2 and a single-centre expe-
rience3. The CE mark trial included 60 selected patients, mainly 
treated by a transfemoral approach (98.3%), and showed favoura-
ble clinical outcomes without death or stroke events at 30-day fol-
low-up2. In order to assess the safety and efficacy of the Evolut R 
device, periprocedural characteristics and clinical outcomes were 
investigated in a real-world patient population and compared with 
the former-generation CoreValve.
Editorial, see page 2161
Methods
The Swiss TAVI registry (ClinicalTrials.gov NCT01368250) is an 
ongoing national, prospective cohort study aiming for consecu-
tive patient enrolment (mandatory for participating centres), data 
monitoring and event adjudication by a clinical events committee 
according to the Valve Academic Research Consortium (VARC)-2 
criteria4,5. Initiated in 2011, the registry was designed to evalu-
ate thoroughly patient characteristics, procedural details as well 
as short- and long-term outcomes after TAVI with CE-approved 
devices6.
For the purposes of this analysis, all patients from the Swiss 
TAVI registry undergoing TAVI with the CoreValve and the 
Evolut R using femoral access were considered eligible. Patients 
were treated with the CoreValve between February 2011 and 
February 2016, whereas the Evolut R was used from September 
2014 (23 mm) and February 2015 (26 and 29 mm) until February 
2016. In the absence of a larger than 29 mm Evolut R device, 
clinical outcomes of patients receiving the CoreValve 31 mm were 
excluded from the main analysis.
The Swiss TAVI registry protocol was approved by the local 
ethics committee at each participating centre. All patients provided 
written informed consent for prospective follow-up assessment. 
The registry was initiated and is performed under the lead of the 
Swiss Cardiovascular Center at Bern University Hospital, Bern, 
Switzerland. The Clinical Trials Unit Bern is responsible for data 
management and independent statistical analysis.
Statistical analysis
Continuous parameters are reported as mean±standard devia-
tion (SD), and categorical variables are reported as numbers of 
patients (% of patients). Events are reported as counts of first 
occurrence per (sub-)type of event within 30 days of follow-up 
(% of all patients). Event rates at 30 days for patients treated 
with the Evolut R versus the CoreValve prosthesis were com-
pared using Cox regressions, censoring patients at death or lost to 
follow-up. Reported are crude hazard ratios (HR with 95% con-
fidence intervals) with p-values from Wald chi-square tests, or 
continuity corrected risk ratios with p-values from Fisher’s exact 
tests in case of zero events in one of the two prosthesis patient 
groups. Reported are adjusted HR (95% CI) using the follow-
ing procedure: 1) 20 data sets were created imputing the miss-
ing values using chained equations (multiple imputation). 2) The 
estimates of the adjusted HR after multiple imputations were 
combined using Rubin’s rule and are presented with adjusted 
p-values. 3) Adjustment was for age (years), history of myocar-
dial infarction, Canadian Cardiovascular Society angina class, 
STS risk score, procedure time (min), amount of contrast dye 
(ml), general anaesthesia and concomitant PCI (selected on the 
basis of an univariable p-value <0.2 comparing the two valves) 
and TAVI procedure date (i.e., potential general learning effect 
over time). No adjusted analyses were performed for outcomes 
with less than five events overall. Two-sided p-values <0.05 were 
considered statistically significant. All analyses were performed 
with Stata version 14 (StataCorp, College Station, TX, USA).
Results
PATIENT POPULATION
During the inclusion period, 317 consecutive patients were treated 
with the Evolut R and 678 patients with the 23 mm, 26 mm, or 
29 mm CoreValve. Baseline clinical characteristics are detailed in 
Table 1: they were well balanced between both groups except for 
the STS and the logistic EuroSCORE, which were significantly 
lower in the Evolut R group (4.8±3.4% vs. 6.9±5.0%, p<0.001; and 
17.3±12.9% vs. 20.1±13.2%, p=0.009, respectively). Specifically, 
no significant differences were found for age (82.1±6.4 vs. 
82.8±6.3 years), gender (females 64.0% vs. 62.1%) and preproc-
edural aortic valve area (0.69±0.2 cm2 vs. 0.69±0.3 cm2) between 
Evolut R and CoreValve patients, respectively.
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PROCEDURAL CHARACTERISTICS
Procedural characteristics are depicted in Table 2. Patients treated 
with the Evolut R had shorter procedural times (67.9±35.6 min vs. 
76.7±41.8 min, p=0.002), received less contrast dye (152.4±90.0 ml 
vs. 208.1±118.9 ml, p<0.001), less frequently required general 
anaesthesia (26.8% vs. 40.7%, p<0.001), and were less frequently 
treated with predilatation (44.5% vs. 71.8%, p<0.001) compared 
with CoreValve patients. Post-procedural mean gradient, aortic 
valve area and PVL were comparable between the two groups.
CLINICAL OUTCOMES
Periprocedural clinical outcomes at 30 days are detailed in 
Table 3. No significant differences were found for death (3.2% vs. 
3.4%, HRadj 1.02, 95% CI: 0.90-1.14), disabling stroke (1.9% vs. 
1.6%, HRadj 1.09, 95% CI: 0.92-1.29), major vascular (9.8% vs. 
10.3%, HRadj 1.01, 95% CI: 0.94-1.08) and bleeding complications 
(18.7% vs. 19.0%, HRadj 1.04, 95% CI: 0.99-1.09). Moreover, 
VARC-2 stage 3 kidney injury (1.9% vs. 2.4%, HRadj 1.08, 95% CI: 
Table 1. Baseline clinical characteristics.
Evolut R
N=317
CoreValve
N=678
p-value
Age (years) 82.1±6.4 82.8±6.3 0.10
Female gender, n (%) 203 (64.0%) 421 (62.1%) 0.57
Body mass index (kg/m²) 26.6±5.9 26.3±5.0 0.41
Cardiac risk factors
Diabetes mellitus, n (%) 72 (22.7%) 180 (26.5%) 0.21
Dyslipidaemia, n (%) 171 (53.9%) 349 (51.5%) 0.50
Hypertension, n (%) 257 (81.3%) 541 (79.8%) 0.61
Past medical history
Previous pacemaker implantation, n (%) 34 (10.7%) 84 (12.4%) 0.53
Previous myocardial infarction, n (%) 38 (12.0%) 83 (12.2%) 1.00
Previous cardiac surgery, n (%) 48 (15.1%) 90 (13.3%) 0.43
Previous cerebrovascular accident, n (%) 42 (13.2%) 72 (10.6%) 0.24
Clinical features
Peripheral vascular disease, n (%) 48 (15.1%) 78 (11.5%) 0.13
Chronic obstructive pulmonary disease, n (%) 37 (11.7%) 98 (14.5%) 0.27
Coronary artery disease, n (%) 157 (49.5%) 355 (52.4%) 0.42
Left ventricular ejection fraction (%)* 57.2±15 55.2±13.8 0.07
Aortic valve area (cm2) * 0.69±0.2 0.69±0.3 0.75
Mean transvalvular gradient (mmHg)* 41.0±18.0 44.3±18.7 0.019
Symptoms on admission
New York Heart Association (NYHA) functional class 0.21
NYHA I or II, n (%) 114 (36.5%) 218 (32.4%) 0.22
NYHA III or IV, n (%) 198 (63.5%) 454 (67.6%) 0.22
Risk assessment
Log. EuroSCORE (%) 17.3±12.9 20.1±13.2 0.009
STS score (%) 4.8±3.4 6.9±5.0 <0.001
Depicted are means with standard deviations (p-value from t-tests) or counts (% of 
all patients; p-value from Fisher’s or chi-square tests).
Table 2. Procedural characteristics.
Evolut R
N=317
CoreValve
N=678
p-value
Procedure time (min) 67.9±35.6 76.7±41.8 0.002
Amount of contrast (ml) 152.4±90.0 208.1±118.9 <0.001
General anaesthesia, n (%) 85 (26.8%) 276 (40.7%) <0.001
Conversion from local to general anaesthesia, 
n (%)
10 (4.3%) 14 (3.5%) 0.67
Device features
Valve size 0.46
23 mm 28 (8.8%) 45 (6.6%) 0.24
26 mm 127 (40.1%) 276 (40.7%) 0.89
29 mm 162 (51.1%) 357 (52.7%) 0.68
Prior balloon aortic valvuloplasty, n (%) 141 (44.5%) 487 (71.8%) <0.001
Post-procedure
Aortic regurgitation post 
TAVI
Grade 0, n (%) 96 (30.5%) 197 (29.3%) 0.71
Grade 1, n (%) 192 (61.0%) 405 (60.2%) 0.83
Grade 2, n (%) 25 (7.9%) 67 (10.0%) 0.35
Grade 3, n (%) 2 (0.6%) 4 (0.6%) 1.00
Mean transprosthetic 
gradient (mmHg)
23 mm 11.0±7.3 11.5±7.2 0.81
26 mm 7.1±4.6 7.2±5.0 0.98
29 mm 7.0±4.0 7.2±4.4 0.61
Aortic valve area (cm2) 23 mm 1.3±0.4 1.3±0.5 0.95
26 mm 1.8±0.5 1.8±0.5 0.85
29 mm 1.8±0.5 2.0±0.5 0.029
Depicted are means with standard deviations (p-values from t-tests) or counts (% of 
all patients; p-values from Fisher’s tests or chi-square tests).
0.92-1.28) and rates of permanent pacemaker (PPM) implantation 
after TAVI were comparable (22.1% vs. 23.4%, HRadj 1.03, 95% 
CI: 0.98-1.08) between the Evolut R and CoreValve patients.
Discussion
Our study is the largest report on periprocedural and 30-day out-
comes comparing the new-generation Evolut R device and the 
previous CoreValve generation in a nationwide prospective cohort 
study of consecutive patients undergoing TAVI. The main findings 
can be summarised as follows:
1. Clinical outcomes at 30 days were favourable with the Evolut R, 
with low morbidity and mortality rates in a consecutive, real-
world patient population.
2. Clinical outcomes of the Evolut R were comparable with the 
previous-generation CoreValve.
3. The procedural duration with the Evolut R was significantly 
shorter, less contrast dye was required and there were lower 
rates of predilatation when compared with the CoreValve.
Valve-related outcomes were similar between the two devices 
with overall low PVL rates and comparable transvalvular gradi-
ents within the respective device sizes.
Despite the lower STS score and the logistic EuroSCORE of 
the Evolut R population, we could not demonstrate a reduction 
in mortality with the new device. However, the observed 30-day 
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Outcomes with Evolut R vs. CoreValve
mortality rates (3.2% for Evolut R and 3.4% for CoreValve) were 
lower than expected according to the STS score. Our results com-
pare well with other national TAVI registries reporting peripro-
cedural mortality rates between 4.2% and 9.7%7-11. Also, our 
mortality rates are comparable to the 30-day results of the new-
generation balloon-expandable Edwards SAPIEN 3 prosthesis 
(Edwards Lifesciences Inc., Irvine, CA, USA) (all-cause mortality 
3.3%) in a similar patient population in Switzerland12.
The Evolut R is currently delivered with the EnVeo-R cath-
eter and the integrated InLine sheath (both Medtronic) – with 
a 14 Fr equivalent profile corresponding to a true 18 Fr outer dia-
meter – allowing sheathless implantation of the Evolut R device. 
With these specifications, the Evolut R is currently considered 
the device with the lowest delivery profile on the market, a fac-
tor potentially reducing the rate of vascular access-related compli-
cations. While Barbanti et al were able to prove this association 
and showed that lower profile sheaths (14 Fr-18 Fr) were linked 
to significantly fewer major vascular complications compared to 
larger vascular access sheath dimensions (19 Fr-24 Fr)13, we were 
not able to show significant differences between the previous-gen-
eration CoreValve device (18 Fr delivery sheath) and the Evolut R 
(14 Fr delivery profile). Indeed, major vascular and access-related 
complications were observed in 10.3% of patients receiving the 
CoreValve and 9.8% of patients receiving the Evolut R (HRadj 
1.01, 95% CI: 0.94-1.08) in the present analysis. However, the 
rate of major vascular complications in our Evolut R patient 
series (9.8%) is comparable with the rate of vascular complica-
tions reported in the Evolut R CE mark trial (8.7%)2 as well as 
in a recent publication from the Swiss TAVI registry in which the 
rate of major vascular complications was 9.3% for the Edwards 
SAPIEN 3 (815 cases) and 7.2% for the Lotus™ valve (140 cases) 
(Boston Scientific, Marlborough, MA, USA)14. A detailed and 
thorough comparison of vascular access-site complication rates 
would demand analyses adjusting for anatomical factors such as 
calcification and tortuosity of the vasculature, the type of access 
to the vessel and the use of different closure devices. Furthermore, 
a specific selection bias cannot be excluded, as the lower profile 
of the Evolut R system might have led to its more frequent use for 
small femoral vasculature and difficult access sites. As a conse-
quence, the benefit of the lower profile may have been counterbal-
anced by challenging anatomical circumstances.
The need for PPM was comparable between devices and amounted 
to 22.1% after the Evolut R and 23.4% after the CoreValve in our 
study. This observation was surprising and unexpectedly high, given 
the low PPM rate in the Evolut R CE mark trial (11.7%)2. However, 
in a recent single-centre report from Heidelberg, the PPM rate 
amounted to 23.3% in 100 Evolut R cases3, which is comparable to 
ours. Previous studies have extensively studied independent predic-
tors of PPM after TAVI with different devices: in addition to indi-
vidual pre-existing conduction disturbances, the device implantation 
Table 3. Clinical outcomes at 30-day follow-up.
Evolut R
N=317
CoreValve
N=678
HR
(95% CI)
p-value Adjusted HR
(95% CI)
p-value
Mortality, n (%) 10 (3.2) 23 (3.4) 0.94 (0.45-1.97) 0.86 1.02 (0.90-1.14) 0.78
Cardiovascular mortality, n (%) 8 (2.5) 22 (3.3) 0.78 (0.35-1.75) 0.55 1.00 (0.88-1.13) 0.94
Cerebrovascular accident, n (%) 15 (4.8) 25 (3.7) 1.29 (0.68-2.44) 0.44 1.04 (0.94-1.16) 0.43
Disabling stroke, n (%) 6 (1.9) 11 (1.6) 1.17 (0.43-3.15) 0.76 1.09 (0.92-1.29) 0.33
Non-disabling stroke, n (%) 8 (2.5) 12 (1.8) 1.43 (0.59-3.51) 0.43 1.03 (0.89-1.19) 0.67
Myocardial infarction, n (%) 0 (0.0) 3 (0.4) 0.31 (0.02-5.98) 0.56
Periprocedural myocardial infarction, n (%) 0 (0.0) 3 (0.4) 0.31 (0.02-5.98) 0.56
Acute kidney injury, n (%) 14 (4.5) 38 (5.7) 0.79 (0.43-1.45) 0.44 1.09 (0.98-1.21) 0.12
Stage 3, n (%) 6 (1.9) 16 (2.4) 0.80 (0.31-2.05) 0.64 1.08 (0.92-1.28) 0.34
Bleeding, n (%) 59 (18.7) 128 (19.0) 0.99 (0.73-1.35) 0.95 1.04 (0.99-1.09) 0.12
Life-threatening or major bleeding, n (%) 40 (12.7) 99 (14.7) 0.86 (0.60-1.24) 0.43 1.04 (0.98-1.10) 0.17
Vascular access-site and access-related 
complications, n (%) 58 (18.4) 123 (18.2) 1.01 (0.74-1.37) 0.97 1.03 (0.98-1.08) 0.30
Major vascular complications, n (%) 31 (9.8) 70 (10.3) 0.94 (0.62-1.44) 0.79 1.01 (0.94-1.08) 0.81
Structural valve deterioration, n (%) 1 (0.3) 0 (0.0) 6.41 (0.26-156.91) 0.32
Repeat unplanned intervention, n (%) 4 (1.3) 5 (0.7) 1.72 (0.46-6.41) 0.42 1.01 (0.81-1.25) 0.95
Valve-in-valve treatment, n (%) 1 (0.3) 1 (0.2) 2.16 (0.13-34.51) 0.59 1.04 (0.69-1.58) 0.85
Surgical revision, n (%) 1 (0.3) 1 (0.1) 2.14 (0.13-34.19) 0.59 0.96 (0.53-1.73) 0.89
Permanent pacemaker implantation, n (%) 69 (22.1) 156 (23.4) 0.95 (0.71-1.26) 0.72 1.03 (0.98-1.08) 0.22
Depicted are number of first events within 30 days with % of all patients. Cox regressions reporting hazard ratio (HR, with 95% confidence intervals); or 
continuity corrected risk ratios (95% CI) in case of zero events with Fisher’s exact p-values. Adjusted HR from Cox regressions combining the results of 
20 multiple-imputed data sets (using Rubin’s rule) controlling for the TAVI procedure date (linear over time) and variables selected on the basis of 
univariable p-value <0.2 comparing the two valves). Multiple imputation of missing data was performed using chained equations to account for missing 
data. 
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depth has been shown to be independently associated with a higher 
rate of conduction abnormalities and the need for PPM after TAVI15. 
Similarly, the rate of PPM after the CoreValve was found to be low-
est (10.6%) in cases where the implantation depth was between 0 
and 6 mm within the left ventricular outflow tract16. The association 
between implantation depth and PPM is similar for the Evolut R. An 
analysis of patients in the CE mark trial2 showed no PPM in patients 
with an implantation depth of 3.3±2.5 mm, and a new PPM in patients 
with an implantation depth of 8.1±3.5 mm. While the Evolut R is 
supposed to be more stable during the implantation phase, thereby 
enhancing the operator positioning accuracy and ensuring an opti-
mal placement in the desired annular position, this did not translate 
into a lower rate of PPM when compared to the previous-genera-
tion CoreValve in our study of unselected, real-world patients. All 
efforts should be made to reduce the rate of conduction disturbances 
and the need for PPM, as conflicting evidence is currently avail-
able on the benign nature of PPM implantation in this setting17,18.
In our study, we observed a significantly lower rate of predila-
tation among patients treated with the Evolut R compared to the 
CoreValve (44.5% vs. 71.8%), which contributed to the shorter 
procedure duration. In order to minimise the interaction with the 
calcified native aortic valve and avoid the risk of embolism of 
calcified debris, there is a general trend of limiting predilatation. 
However, there is conflicting evidence in the literature on the 
safety of direct valve implantation. While some small series report 
similar outcomes after valve implantation without predilatation19,20, 
some others provide evidence of a higher rate of major adverse 
cardiac and cerebrovascular events (MACCE) mainly driven 
by an increased risk of stroke during the periprocedural period 
among patients treated without predilatation21. The effect of pre-
dilatation on clinical outcome is being assessed in the randomised 
“Transcatheter Aortic Valve Implantation Without Predilatation 
(SIMPLIFy-TAVI) study” (NCT01539746) and the “Balloon 
Expandable Transcatheter Aortic Valve Implantation Without 
Predilatation of Aortic Valve (EASE-IT) study” (NCT02127580) 
which will shed further light on this issue.
Rates of significant PVL (i.e., ≥2) were comparable and without 
significant differences between the Evolut R and the CoreValve in 
this study (8.5% vs. 10.6%). While the rate with the Evolut R was 
found to be higher compared with the rate in the CE mark trial 
(8.5% vs. 3.4%)2, our results with the CoreValve are in line with 
the rate of PVL ≥2 reported in the US pivotal trials (10.7% for 
extreme risk, 9.0% for high-risk patients)22,23. In comparison, the 
rate of PVL ≥2 with the SAPIEN 3 was 3.4% in the largest series 
(>1,600 patients)24 and 3.5% in the first multicentre trial including 
150 patients25, whereas, in the previous report of the Swiss TAVI 
registry, the rate of PVL ≥2 was 1.3%12. The Lotus valve has also 
shown a low rate of PVL ≥2 at 1.9% in the REPRISE-II study26.
Limitations
The results of the present study need to be interpreted with the 
following limitations. First, the number of patients is limited in 
the Evolut R group and, for the purposes of this analysis, only 
periprocedural events have been used to focus on potential dif-
ferences with the previous-generation CoreValve device. Second, 
periprocedural results are self-reported and, in the absence of a cen-
tral core laboratory for the evaluation of echocardiographic results, 
there might be some heterogeneity in the assessment of PVL. 
However, PVL was assessed by experienced echocardiographers for 
both devices, which reduces centre-specific assessment as a con-
founder. Third, serious adverse events were self-reported; however, 
all subjects underwent central data monitoring and events were sys-
tematically adjudicated by a dedicated clinical events committee 
using VARC-2 criteria. Fourth, no technical or specific details on the 
procedure itself are available, including rates of valvular re-sheath-
ing and numbers of valve placement attempts for the Evolut R as 
well as the number of predilatations or post-dilatations, which might 
all have an impact on procedural results. Finally, no detailed infor-
mation on vascular access-site anatomy was collected, precluding 
a sophisticated and thorough analysis investigating the benefit of the 
lower vascular sheath dimensions of the Evolut R, and no detailed 
information on the device implantation depth was collected in order 
to correlate the PPM rate and implantation depth.
Conclusions
The use of the new-generation Evolut R self-expanding prosthe-
sis is associated with low morbidity and mortality rates at 30-day 
follow-up. Overall, the results of the Evolut R appear comparable 
to the Medtronic CoreValve THV. The use of the Evolut R device 
appears to facilitate a faster and simpler TAVI procedure as the 
duration is shorter, more commonly performed under local anaes-
thesia and with less contrast dye. Longer-term follow-up is needed 
to compare the two devices further with respect to PVL evolution.
Impact on daily practice
In a consecutive, real-world patient population, 30-day clini-
cal outcomes of the new-generation Evolut R self-expand-
ing prosthesis were comparable with the previous-generation 
CoreValve. Valve-related outcomes were also similar between 
the two devices, with overall low PVL rates and comparable 
transvalvular gradients within the respective device sizes. The 
use of the Evolut R device appears to facilitate a faster and sim-
pler TAVI procedure as the duration is shorter, more commonly 
performed under local anaesthesia and with less contrast dye.
Funding
The Swiss TAVI registry is supported (unrestricted funding) by: 
Swiss Working Group of Interventional Cardiology, Swiss Heart 
Foundation, Boston Scientific, Edwards Lifesciences, Medtronic, 
St. Jude Medical.
Conflict of interest statement
S. Noble serves as a consultant to Medtronic. M. Roffi has 
received institutional research grants from Abbott Vascular, Boston 
Scientific, Biotronik, Biosensors and Medtronic. R. Jeger serves as 
e2175
EuroIntervention 2
0
17;1
2
:e
2170
-e
2176
Outcomes with Evolut R vs. CoreValve
a consultant to St. Jude Medical and has received reimbursement 
for travel expenses from Medtronic, Boston Scientific and Edwards 
Lifesciences. S. Toggweiler has received speaker fees from Edwards 
Lifesciences, Symetis and Medtronic, and is a Symetis proctor and 
consultant for NVT. E. Ferrari is an Edwards Lifesciences proc-
tor. P. Jüni is an unpaid steering committee or statistical execu-
tive committee member of trials funded by Abbott Vascular, 
Biosensors, Medtronic and Johnson & Johnson. F. Nietlispach 
serves as a consultant to Edwards Lifesciences, Medtronic, St. Jude 
Medical, 4Tech and has received speaker’s fees from Biotronik. 
M. Taramasso serves as a consultant for St. Jude Medical. C. Huber 
is an Edwards Lifesciences proctor and consultant for Medtronic. 
S. Windecker has received institutional research contracts from 
Abbott, Boston Scientific, Biosensors, Cordis, Medtronic, Biotronik, 
Edwards Lifesciences and St. Jude. P. Wenaweser serves as proc-
tor for Medtronic, Edwards Lifesciences and Boston Scientific, 
and has received an unrestricted institutional grant from Medtronic 
(University of Bern). CTU Bern (part of Bern University) has a staff 
policy of not accepting honoraria or consultancy fees. However, 
CTU Bern is involved in the design, conduct or analysis of clini-
cal studies funded by the industry. D. Tueller received speaker fees 
from Edwards Lifesciences and travel expenses from Medtronic. 
F. Maisano is a consultant for Medtronic, Edwards Lifesciences, 
St. Jude, Abbott Vascular and Valtech Cardio and he receives royal-
ties from Edwards. The other authors have no conflicts of interest 
to declare.
References
 1. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, 
Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. 
Percutaneous transcatheter implantation of an aortic valve prosthe-
sis for calcific aortic stenosis: first human case description. 
Circulation. 2002;106:3006-8.
 2. Manoharan G, Walton AS, Brecker SJ, Pasupati S, 
Blackman DJ, Qiao H, Meredith IT. Treatment of Symptomatic 
Severe Aortic Stenosis With a Novel Resheathable Supra-Annular 
Self-Expanding Transcatheter Aortic Valve System. JACC 
Cardiovasc Interv. 2015;8:1359-67.
 3. Gomes B, Geis NA, Chorianopoulos E, Meder B, Leuschner F, 
Katus HA, Bekeredjian R. Improvements of Procedural Results 
With a New-Generation Self-Expanding Transfemoral Aortic Valve 
Prosthesis in Comparison to the Old-Generation Device. J Interv 
Cardiol. 2017;30:72-78.
 4. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, 
Kappetein AP, Krucoff MW, Mack M, Mehran R, Miller C, 
Morel MA, Petersen J, Popma JJ, Takkenberg JJ, Vahanian A, van 
Es GA, Vranckx P, Webb JG, Windecker S, Serruys PW. 
Standardized endpoint definitions for transcatheter aortic valve 
implantation clinical trials: a consensus report from the Valve 
Academic Research Consortium. Eur Heart J. 2011;32:205-17.
 5. Kappetein AP, Head SJ, Généreux P, Piazza N, van 
Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, 
van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, 
Mack MJ, Mehran R, Rodés-Cabau J, Vranckx P, Webb JG, 
Windecker S, Serruys PW, Leon MB. Updated standardized end-
point definitions for transcatheter aortic valve implantation: the 
Valve Academic Research Consortium-2 consensus document. Eur 
Heart J. 2012;33:2403-18.
 6. Wenaweser P, Stortecky S, Heg D, Tueller D, Nietlispach F, 
Falk V, Pedrazzini G, Jeger R, Reuthebuch O, Carrel T, Räber L, 
Amann FW, Ferrari E, Toggweiler S, Noble S, Roffi M, 
Gruenenfelder J, Jüni P, Windecker S, Huber C. Short-term clini-
cal outcomes among patients undergoing transcatheter aortic 
valve implantation in Switzerland: the Swiss TAVI registry. 
EuroIntervention. 2014;10:982-9.
 7. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, 
Chevreul K, Fajadet J, Leprince P, Leguerrier A, Lievre M, Prat A, 
Teiger E, Lefevre T, Himbert D, Tchetche D, Carrié D, Albat B, 
Cribier A, Rioufol G, Sudre A, Blanchard D, Collet F, Dos Santos P, 
Meneveau N, Tirouvanziam A, Caussin C, Guyon P, Boschat J, Le 
Breton H, Collart F, Houel R, Delpine S, Souteyrand G, Favereau X, 
Ohlmann P, Doisy V, Grollier G, Gommeaux A, Claudel JP, 
Bourlon F, Bertrand B, Van Belle E, Laskar M; FRANCE 2 
Investigators. Registry of transcatheter aortic-valve implantation in 
high-risk patients. N Engl J Med. 2012;366:1705-15.
 8. Snow TM, Ludman P, Banya W, DeBelder M, MacCarthy PM, 
Davies SW, Di Mario C, Moat NE. Management of concomitant 
coronary artery disease in patients undergoing transcatheter aortic 
valve implantation: the United Kingdom TAVI Registry. Int J 
Cardiol. 2015;199:253-60.
 9. Eggebrecht H, Mehta RH, Haude M, Sack S, Mudra H, 
Hein R, Brachmann J, Gerckens U, Kuck KH, Zahn R, Sechtem U, 
Richardt G, Schneider S, Senges J. Transcatheter aortic valve 
implantation (TAVI) by centres with and without an on-site cardiac 
surgery programme: preliminary experience from the German 
TAVI registry. EuroIntervention. 2014;10:602-8.
 10. Collas VM, Dubois C, Legrand V, Kefer J, De Bruyne B, 
Dens J, Rodrigus IE, Herijgers P, Bosmans JM; Belgian TAVI 
Registry Participants. Midterm clinical outcome following Edwards 
SAPIEN or Medtronic Corevalve transcatheter aortic valve implan-
tation (TAVI): Results of the Belgian TAVI registry. Catheter 
Cardiovasc Interv. 2015;86:528-35.
 11. Barbanti M, Petronio AS, Ettori F, Latib A, Bedogni F, De 
Marco F, Poli A, Boschetti C, De Carlo M, Fiorina C, Colombo A, 
Brambilla N, Bruschi G, Martina P, Pandolfi C, Giannini C, 
Curello S, Sgroi C, Gulino S, Patane M, Ohno Y, Tamburino C, 
Attizzani GF, Imme S, Gentili A, Tamburino C. 5-Year Outcomes 
After Transcatheter Aortic Valve Implantation With CoreValve 
Prosthesis. JACC Cardiovasc Interv. 2015;8:1084-91.
 12. Binder RK, Stortercky S, Heg D, Tueller D, Jeger R, 
Toggweiler S, Pedrazzini G, Amann FW, Ferrari E, Noble S, 
Nietlispach F, Maisano F, Räber L, Roffi M, Grünenfelder J, Jüni P, 
Huber C, Windecker S, Wenaweser P. Procedural Results and Clinical 
Outcomes of Transcatheter Aortic Valve Implantation in Switzerland: 
An Observational Cohort Study of Sapien 3 Versus Sapien XT 
Transcatheter Heart Valves. Circ Cardiovasc Interv. 2015;8(10).
e2176
EuroIntervention 2
0
17;1
2
:e
2170
-e
2176
 13. Barbanti M, Binder RK, Freeman M, Wood DA, Leipsic J, 
Cheung A, Ye J, Tan J, Toggweiler S, Yang TH, Dvir D, Maryniak K, 
Lauck S, Webb JG. Impact of low-profile sheaths on vascular com-
plications during transfemoral transcatheter aortic valve replace-
ment. EuroIntervention. 2013;9:929-35.
 14. Pilgrim T, Stortecky S, Nietlispach F, Heg D, Tueller D, 
Toggweiler S, Ferrari E, Noble S, Maisano F, Jeger R, Roffi M, 
Grunenfelder J, Huber C, Wenaweser P, Windecker S. Repositionable 
Versus Balloon-Expandable Devices for Transcatheter Aortic Valve 
Implantation in Patients With Aortic Stenosis. J Am Heart Assoc. 
2016;5(11).
 15. Aktug O, Dohmen G, Brehmer K, Koos R, Altiok E, 
Deserno V, Herpertz R, Autschbach R, Marx N, Hoffmann R. 
Incidence and predictors of left bundle branch block after trans-
catheter aortic valve implantation. Int J Cardiol. 2012;160:26-30.
 16. Tchetche D, Modine T, Farah B, Vahdat O, Sudre A, 
Koussa M, Lereun C, Nejjari M, Choby M, Rosencher J, Sorbets E, 
Fajadet J. Update on the need for a permanent pacemaker after 
transcatheter aortic valve implantation using the CoreValve® 
Accutrak™ system. EuroIntervention. 2012;8:556-62.
 17. Dizon JM, Nazif TM, Hess PL, Biviano A, Garan H, Douglas PS, 
Kapadia S, Babaliaros V, Herrmann HC, Szeto WY, Jilaihawi H, 
Fearon WF, Tuzcu EM, Pichard AD, Makkar R, Williams M, Hahn RT, 
Xu K, Smith CR, Leon MB, Kodali SK; PARTNER Publications 
Office. Chronic pacing and adverse outcomes after transcatheter aor-
tic valve implantation. Heart. 2015;101:1665-71.
 18. Buellesfeld L, Stortecky S, Heg D, Hausen S, Mueller R, 
Wenaweser P, Pilgrim T, Gloekler S, Khattab AA, Huber C, 
Carrel T, Eberle B, Meier B, Boekstegers P, Jüni P, Gerckens U, 
Grube E, Windecker S. Impact of permanent pacemaker implanta-
tion on clinical outcome among patients undergoing transcatheter 
aortic valve implantation. J Am Coll Cardiol. 2012;60:493-501.
 19. Grube E, Naber C, Abizaid A, Sousa E, Mendiz O, Lemos P, 
Kalil Filho R, Mangione J, Buellesfeld L. Feasibility of trans-
catheter aortic valve implantation without balloon pre-dilation: 
a pilot study. JACC Cardiovasc Interv. 2011;4:751-7.
 20. Fiorina C, Maffeo D, Curello S, Lipartiti F, Chizzola G, 
D’Aloia A, Adamo M, Mastropierro R, Gavazzi E, Ciccarese C, 
Chiari E, Ettori F. Direct transcatheter aortic valve implantation 
with self-expandable bioprosthesis: feasibility and safety. 
Cardiovasc Revasc Med. 2014;15:200-3.
 21. Pagnesi M, Jabbour RJ, Latib A, Kawamoto H, Tanaka A, 
Regazzoli D, Mangieri A, Montalto C, Ancona MB, Giannini F, 
Chieffo A, Montorfano M, Monaco F, Castiglioni A, Alfieri O, 
Colombo A. Usefulness of Predilation Before Transcatheter 
Aortic Valve Implantation. Am J Cardiol. 2016;118:107-12.
 22. Popma JJ, Adams DH, Reardon MJ, Yakubov SJ, Kleiman NS, 
Heimansohn D, Hermiller J Jr, Hughes GC, Harrison JK, Coselli J, 
Diez J, Kafi A, Schreiber T, Gleason TG, Conte J, Buchbinder M, 
Deeb GM, Carabello B, Serruys PW, Chenoweth S, Oh JK; 
CoreValve United States Clinical Investigators. Transcatheter aor-
tic valve replacement using a self-expanding bioprosthesis in 
patients with severe aortic stenosis at extreme risk for surgery. J Am 
Coll Cardiol. 2014;63:1972-81.
 23. Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, 
Deeb GM, Gleason TG, Buchbinder M, Hermiller J Jr, Kleiman NS, 
Chetcuti S, Heiser J, Merhi W, Zorn G, Tadros P, Robinson N, 
Petrossian G, Hughes GC, Harrison JK, Conte J, Maini B, 
Mumtaz M, Chenoweth S, Oh JK; U.S. CoreValve Clinical 
Investigators. Transcatheter aortic-valve replacement with a self-
expanding prosthesis. N Engl J Med. 2014;370:1790-8.
 24. Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, 
Greason KL, Williams M, Guerrero M, Eisenhauer AC, 
Kapadia S, Kereiakes DJ, Herrmann HC, Babaliaros V, 
Szeto WY, Hahn RT, Pibarot P, Weissman NJ, Leipsic J, Blanke P, 
Whisenant BK, Suri RM, Makkar RR, Ayele GM, Svensson LG, 
Webb JG, Mack MJ, Smith CR, Leon MB. Early clinical and 
echocardiographic outcomes after SAPIEN 3 transcatheter aor-
tic valve replacement in inoperable, high-risk and intermediate-
risk patients with aortic stenosis. Eur Heart J. 2016;37: 
2252-62.
 25. Webb J, Gerosa G, Lefèvre T, Leipsic J, Spence M, Thomas M, 
Thielmann M, Treede H, Wendler O, Walther T. Multicenter evalu-
ation of a next-generation balloon-expandable transcatheter aortic 
valve. J Am Coll Cardiol. 2014;64:2235-43.
 26. Meredith Am IT, Walters DL, Dumonteil N, Worthley SG, 
Tchetche D, Manoharan G, Blackman DJ, Rioufol G, Hildick-
Smith D, Whitbourn RJ, Lefevre T, Lange R, Muller R, Redwood S, 
Allocco DJ, Dawkins KD. Transcatheter aortic valve replacement 
for severe symptomatic aortic stenosis using a repositionable valve 
system: 30-day primary endpoint results from the REPRISE II 
study. J Am Coll Cardiol. 2014;64:1339-48.
